Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 40.06
-0.42 (-1.04%)
Aug 12, 2026, 9:22 AM CET
Hansa Biopharma AB Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Hansa Biopharma AB stock has a consensus rating of "Strong Buy" and an average price target of kr 73.00. The average 1-year stock price forecast is 82.23% higher than the current stock price, while the lowest is kr 36.00 (-10.13%) and the highest is kr 103.00 (+157.11%).
Price Target: kr 73.00 (+82.23%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hansa Biopharma AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates kr 103.00 | Buy | Reiterates | kr 103.00 | +157.11% | Jul 23, 2026 |
Financial Forecast
Revenue This Year
952.01M
from 222.27M
Increased by 328.32%
Revenue Next Year
438.25M
from 952.01M
Decreased by -53.97%
EPS This Year
1.50
from -5.79
EPS Next Year
-5.54
from 1.50
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.